Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Anti-Human MET/c-Met/HGFR (Sym-015)

Catalog #:   DHC34216 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC34216

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG

Clonality

Monoclonal

Target

Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08581

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Sym-015, Sym 015, Sym015

Clone ID

Sym-015

Data Image
References

Prevalence of dengue in febrile patients in Peru: A systematic review and meta-analysis., PMID:40526741

Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial., PMID:40526384

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090

Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis., PMID:40524797

Interventions for central serous chorioretinopathy: a network meta-analysis., PMID:40522203

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system., PMID:40520157

Interlaboratory study to assess precision and reproducibility of the meningococcal antigen surface expression (MEASURE) assay to quantify factor H binding protein expression at the surface of meningococcal serogroup B strains., PMID:40517645

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer., PMID:40515479

Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders., PMID:40505071

The use of Bevacizumab in the treatment of brain arteriovenous malformations: a systematic review., PMID:40504282

IFITM3 deficient mice as a model for testing influenza virus vaccines., PMID:40501891

Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study., PMID:40501126

Impact of Universal Screening for HDV in HBV-Infected Patients on Chronic HDV Detection Rate in Israel., PMID:40497662

Seroprevalence of tick-borne infections in blood donors in Europe: a systematic review., PMID:40497133

Anti-NMDAR Encephalitis With Serial Negative MRI Findings: An Evaluation Using Autoimmune Psychosis Criteria., PMID:40496240

Induction With Antithymocyte Globulin Is Associated With Decreased Mortality and PTLD in Pediatric Liver Transplantation: A UNOS Data Analysis., PMID:40490923

Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma., PMID:40489635

Impact of sirtuin‑1 expression on progression‑free survival in non‑endometrioid endometrial cancer: A retrospective cohort study., PMID:40486084

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial., PMID:40483169

Tumefactive demyelination as the first presentation of MOG ab-associated disease., PMID:40479755

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial., PMID:40474841

Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022., PMID:40473981

Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies., PMID:40471555

A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors., PMID:40465170

Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years., PMID:40464662

Effects of cottonseed meal bioactive peptides on growth performance, ileal digestibility, serum amino acid and immune responses of broiler chickens., PMID:40464591

Humoral immune response following the third dose of BNT162b2 received by employees at a Slovak cancer healthcare facility., PMID:40463399

Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data., PMID:40462491

Association of cancer and anti-synthetase syndrome: a retrospective multicentre study., PMID:40460913

Genetics in a Danish Common Variable Immunodeficiency Cohort., PMID:40455168

Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial., PMID:40450141

Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial., PMID:40450051

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial., PMID:40447851

Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer., PMID:40446773

The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment., PMID:40445574

Clinical spectrum and long-term outcomes of antibody-negative severe autoimmune encephalitis: a retrospective study., PMID:40443652

Adverse Cutaneous Reactions to Monoclonal Antibodies: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Erythema Multiforme, and Fixed Drug Eruption - A Systematic Review., PMID:40443459

Serum antineuronal antibodies in patients with post-COVID-19 condition - association to intensive care., PMID:40441540

PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis., PMID:40440581

Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer., PMID:40440007

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib., PMID:40439479

Incidence of catheter-related bloodstream infection (CRBSI) in immunosuppressed hosts post solid organ transplant (SOT): a single center experience., PMID:40438131

Latin American RAND/UCLA modified Delphi consensus recommendations for management and treatment of adult MOGAD patients in clinical practice., PMID:40435656

The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial., PMID:40432079

Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials., PMID:40430899

Q Fever-Related Community Infections: United States Exposure to Coxiella burnetii., PMID:40430780

Cellular Metabolic Disorders in a Cohort of Patients with Sjogren's Disease., PMID:40429812

High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease., PMID:40424081

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study., PMID:40413619

Datasheet
$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Anti-Human MET/c-Met/HGFR (Sym-015) [DHC34216]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only